Mosliciguat

Small molecule

Also known as BAY 1211163

Phase 3underway

Evidence outlook · registrational

Pulmonary Hypertension Associated with Interstitial Lung Disease: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2029-01-28. The sponsor reported topline results of a Phase 2 study on 2026-09-08 (Phase 2 PHocus of inhaled mosliciguat in PH-ILD met its primary endpoint); that is not the registrational readout.

Latest reported trial: PHocus (NCT06635850) · Phase 2 · met primary endpoint · grade pending

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Pulmonary Hypertension Associated with Interstitial Lung Disease
Phase 2 (2)
Pulmonary Hypertension Associated with Interstitial Lung Disease
NCT07333183 · Pulmovant, Inc.
2025-12-23 – 2028-01 · Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
What this study did
Phase 1 (3)

Competitive landscape

5 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Pulmonary Hypertension Associated with Interstitial Lung Disease: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mosliciguat: this drugPhase 3Small moleculeSoluble guanylate cyclasenot yet gradedNo reviewed efficacy summary in this indication
Riociguat (Adempas)
Approved(overall)
Small moleculeSoluble guanylate cyclase
Reliable signal(overall)
No reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT02630316: Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results).
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Vericiguat (Verquvo)
Approved(overall)
Small moleculeSoluble guanylate cyclase
Reliable signal(overall)
No reviewed efficacy summary in this indication
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Fc-Relaxin Fusion Protein (TX45)Phase 2Protein / enzyme therapeuticRelaxin receptor (RXFP1) / relaxinnot yet gradedNo reviewed efficacy summary in this indication
LAM-001Phase 2Small moleculemTOR (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
MirivadelgatPhase 2Small moleculeALDH2not yet gradedNo reviewed efficacy summary in this indication
Nurandociguat
Phase 2(overall)
Small moleculeSoluble guanylate cyclase
Partial signal(overall)
No reviewed efficacy summary in this indication
Praliciguat
Phase 2(overall)
Small moleculeSoluble guanylate cyclase
not yet graded(overall)
No reviewed efficacy summary in this indication
SK-08
Phase 1(overall)
Small moleculeSoluble guanylate cyclase
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Mosliciguat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Pulmonary Hypertension Associated with Interstitial Lung DiseaseRecruiting
Est. primary completion 2026-12 · NCT07333183 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 3Pulmonary Hypertension Associated with Interstitial Lung DiseaseRecruiting
Est. primary completion 2029-01-28 · NCT07816185 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultPhase 2 PHocus of inhaled mosliciguat in PH-ILD met its primary endpoint
Roivant Sciences Ltd. · Source ↗
10 September 2024Topline resultPhase 1b ATMOS proof-of-concept results for inhaled mosliciguat